The Phase 3 portion of the Orbit study for UX143 shows progress and is on track for a final analysis by the end of the year, suggesting effective management of the clinical trial timeline. The Data ...
THE WOODLANDS, Texas, Nov. 26, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced the completion of patient enrollment in the PROGRESS (A Phase 2b, Dose-ranging, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback